Heart failure & cardiomyopathies
Benefit of cardiac resynchronization therapy among older patients: A patient-level meta-analysis
Authors' conclusion
Reductions in HFH and mortality with CRT are as great or greater in appropriately indicated older patients.
Study context
- Population
- Patients with heart failure (HF) from 8 randomised trials published 2002–2013; median age 67 years, 2436 (38%) aged 70+
- Participants
- 6,369 patients8 RCTs
- Comparison
- Cardiac resynchronization therapy (CRT) vs no CRT, by age
- Outcome
- Composite of:
- HFH or all-cause mortality
- All-cause mortality alone
- Interaction with age (<70 vs ≥70 years or continuous)
Methodological detailsadjusted Bayesian survival model, age interaction analysis
- Adjusted Bayesian survival model
- Age interaction analysis
Pooled result
As reported in the abstract
- Age categorical (<70 vs ≥70 years): no interaction for either end point
- P > .1
- Age continuous: greater benefit in older patients, composite end point (interaction P)
- P for interaction = .027
- Age continuous: similar nonsignificant trend, mortality (interaction P)
- P for interaction = .35
Further pooled results
| Outcome | aHR (95% CrI) | P value | |
|---|---|---|---|
| Composite HFH or all-cause mortality, overallCredible interval | 0.75 (0.66–0.85) | P = 0.002 | |
| All-cause mortality, overallCredible interval | 0.80 (0.69–0.96) | P = 0.017 | |
| 0.512Adjusted hazard ratio (log scale) |
- Composite heart failure hospitalizations (HFH) or all-cause mortality, overall: 95% credible interval (CrI)
- All-cause mortality, overall: 95% credible interval (CrI)
Original publication
Benefit of cardiac resynchronization therapy among older patients: A patient-level meta-analysis. Am Heart J. Published 19 November 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →